Bodycote (BOY LN) Deterioration in sales; profit guidance reiterated | Carador Income Fund (CIFU LN) IMS, recent portfolio activity and market overview | Carclo (CAR LN) Strong H1; move to Buy
| Cyprotex (CRX LN) chemTox solution launched to predict pre-clinical toxicity | Devro (DVO LN) An in line Q3 update with key sentiment drivers on track | Entertainment One Ltd (ETO LN) Strong profit but mix changing rapidly | Futura Medical (FUM LN) Erectile dysfunction trial on track | Halma (HLMA LN) ....
17 Nov 2015
Morning Song
Bodycote plc (BOY:LON), 670 | Carclo plc (CAR:LON), 70.5 | Cyprotex (CRX:LON), 0 | Entertainment One (ETO:LON), 0 | Futura Medical plc (FUM:LON), 2.9 | Halma plc (HLMA:LON), 3,565 | Idox PLC (IDOX:LON), 55.9 | Karolinska Development AB Class B (0P3C:LON), 0 | Lavendon Group (LVD:LON), 0 | Renold plc (RNO:LON), 81.7 | Tribal Group plc (TRB:LON), 66.5
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Morning Song
Bodycote plc (BOY:LON), 670 | Carclo plc (CAR:LON), 70.5 | Cyprotex (CRX:LON), 0 | Entertainment One (ETO:LON), 0 | Futura Medical plc (FUM:LON), 2.9 | Halma plc (HLMA:LON), 3,565 | Idox PLC (IDOX:LON), 55.9 | Karolinska Development AB Class B (0P3C:LON), 0 | Lavendon Group (LVD:LON), 0 | Renold plc (RNO:LON), 81.7 | Tribal Group plc (TRB:LON), 66.5
- Published:
17 Nov 2015 -
Author:
Singer CM Team -
Pages:
29 -
Bodycote (BOY LN) Deterioration in sales; profit guidance reiterated | Carador Income Fund (CIFU LN) IMS, recent portfolio activity and market overview | Carclo (CAR LN) Strong H1; move to Buy
| Cyprotex (CRX LN) chemTox solution launched to predict pre-clinical toxicity | Devro (DVO LN) An in line Q3 update with key sentiment drivers on track | Entertainment One Ltd (ETO LN) Strong profit but mix changing rapidly | Futura Medical (FUM LN) Erectile dysfunction trial on track | Halma (HLMA LN) ....